Patient-Reported Health Outcomes After Treatment of COVID-19 with Nebulized and/or Intravenous Neutral Electrolyzed Saline
HOCl Trust Introduction
New evidence for the effectiveness of HOCl in the treatment of Covid-19 patients.
Patient-Reported Health Outcomes After Treatment of COVID-19 with Nebulized and/or Intravenous Neutral Electrolyzed Saline Combined with Usual Medical Care Versus Usual Medical care alone: A Randomized, Open-Label, Controlled Trial (Preprint)
Author/Source: et al., Research square
Abstract
A clinical trial using volunteer patients, all diagnosed as positive for Covid-19. Both control (n=45), and the experimental group (n=39) were all given appropriate conventional medical therapies and support. The experimental group were, in addition, prescribed HOCl treatment firstly in nebulised form (inhalation of fine droplets) and in rising levels, by intravenous delivery.
31% of the patients without HOCl care deteriorated and were hospitalised, but only 11% of the experimental group required hospital care at a later date.
13% of the control group died, but no deaths were seen in the experimental group treated with escalating doses of HOCl.
The experimental group patients also reported a faster rate of recovery.